Trial Profile
Effects of Sitagliptin on Glycemic Control and Lipoprotein Metabolism (GLORIA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Aug 2018
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GLORIA
- 09 Jun 2015 Primary endpoint Biomarker levels has been met as per abstract presented at 75th Annual Scientific Sessions of the American Diabetes Association.
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 02 Jun 2015 Status changed from recruiting to completed as reported by UMIN record.